Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BOSTON, Oct. 03, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced data from its completed Phase 2 study of lead product candidate A4250 in children with cholestatic liver disease will be presented during a poster session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2017, being held October 20-24, 2017, at the Walter E. Washington Convention Center in Washington, D.C.
Details of the presentation are as follows:
Title: The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study (Abstract #1200)
Session: Poster Session II
Date/Time: October 21, 2017, from 5:30 to 7:00 p.m. ET
Location: Walter E. Washington Convention Center, Hall D
Presenter: Dr. Ekkehard Sturm, Head of Pediatric Gastroenterology and Hepatology, University Hospital Tuebingen, Germany
Abstracts for the meeting can be viewed in the October issue of HEPATOLOGY.
The Liver Meeting®, the 68th Annual Meeting of the AASLD, brings together more than 9,500 physicians, researchers and health professionals from around the world to discuss and advance the science and practice of hepatology. For more information about the meeting, visit: www.aasld.org/events-professional-development/liver-meeting.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]
